224 related articles for article (PubMed ID: 29989024)
1. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
Annels NE; Arif M; Simpson GR; Denyer M; Moller-Levet C; Mansfield D; Butler R; Shafren D; Au G; Knowles M; Harrington K; Vile R; Melcher A; Pandha H
Mol Ther Oncolytics; 2018 Jun; 9():1-12. PubMed ID: 29989024
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
Relph K; Annels N; Smith C; Kostalas M; Pandha H
Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
[TBL] [Abstract][Full Text] [Related]
3. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
Annels NE; Mansfield D; Arif M; Ballesteros-Merino C; Simpson GR; Denyer M; Sandhu SS; Melcher AA; Harrington KJ; Davies B; Au G; Grose M; Bagwan I; Fox B; Vile R; Mostafid H; Shafren D; Pandha HS
Clin Cancer Res; 2019 Oct; 25(19):5818-5831. PubMed ID: 31273010
[TBL] [Abstract][Full Text] [Related]
4. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
[TBL] [Abstract][Full Text] [Related]
5. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
Skelding KA; Barry RD; Shafren DR
Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
[TBL] [Abstract][Full Text] [Related]
6. Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21.
Relph K; Arif M; Pandha H; Annels N; Simpson GR
Methods Mol Biol; 2023; 2684():319-327. PubMed ID: 37410244
[TBL] [Abstract][Full Text] [Related]
7. Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy.
Burnett WJ; Burnett DM; Parkman G; Ramstead A; Contreras N; Gravley W; Holmen SL; Williams MA; VanBrocklin MW
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503272
[TBL] [Abstract][Full Text] [Related]
8. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
[TBL] [Abstract][Full Text] [Related]
9. Applications of coxsackievirus A21 in oncology.
Bradley S; Jakes AD; Harrington K; Pandha H; Melcher A; Errington-Mais F
Oncolytic Virother; 2014; 3():47-55. PubMed ID: 27512662
[TBL] [Abstract][Full Text] [Related]
10. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
11. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21.
Skelding KA; Barry RD; Shafren DR
Breast Cancer Res Treat; 2009 Jan; 113(1):21-30. PubMed ID: 18256929
[TBL] [Abstract][Full Text] [Related]
12. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21.
Au GG; Lindberg AM; Barry RD; Shafren DR
Int J Oncol; 2005 Jun; 26(6):1471-6. PubMed ID: 15870858
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
Au GG; Lincz LF; Enno A; Shafren DR
Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.
Holmes M; Scott GB; Heaton S; Barr T; Askar B; Müller LME; Jennings VA; Ralph C; Burton C; Melcher A; Hillmen P; Parrish C; Errington-Mais F
Mol Ther Oncolytics; 2023 Jun; 29():17-29. PubMed ID: 37077714
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
Johansson ES; Xing L; Cheng RH; Shafren DR
J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
[TBL] [Abstract][Full Text] [Related]
16. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.
Newcombe NG; Johansson ES; Au G; Lindberg AM; Barry RD; Shafren DR
J Virol; 2004 Feb; 78(3):1431-9. PubMed ID: 14722298
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Mesenchymal Stem Cells Loaded with Oncolytic Coxsackievirus A21 on Mouse Models of Colorectal Cancer.
Karbalaee R; Mehdizadeh S; Ghaleh HEG; Izadi M; Kondori BJ; Dorostkar R; Hosseini SM
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38310465
[TBL] [Abstract][Full Text] [Related]
18. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western.
Gillespie PF; Rustandi RR; Swartz AR; Shang L; Raffaele J; Prout A; Cunningham N; Dawod M; Deng JZ; Wang S; Olson J; Shieh Y; Loughney JW
Hum Gene Ther; 2023 Jan; 34(1-2):68-77. PubMed ID: 36503264
[TBL] [Abstract][Full Text] [Related]
20. Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.
Newcombe NG; Beagley LG; Christiansen D; Loveland BE; Johansson ES; Beagley KW; Barry RD; Shafren DR
J Virol; 2004 Nov; 78(22):12677-82. PubMed ID: 15507656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
